- The primary endpoint, fusion (defined as at least 50% osseous bridging) on 24 week CT scans, is highly reproducible based on new blinded inter-observer assessments. The Company contracted with an independent radiology contract research organization, which provided an independent board certified radiologist to read all 24-week CT scans for the primary endpoint to determine inter-observer reliability. These assessments demonstrate strong inter-observer correlation (95%), kappa (0.72) and concordance (87%).
- There is also high intra-observer reliability when assessing the primary endpoint. Per the FDA’s request, the Company also contracted with the original board certified musculoskeletal radiologist to re-read all 24-week CT scans to determine intra-observer reliability. These assessments demonstrate strong intra-observer correlation (99%), kappa (0.87) and concordance (95%).
- The new composite endpoint, specifically defined and requested by the FDA, met statistical significance for all populations, including the 434 strict ITT (all randomized subjects) population.
- When patients who experienced a serious adverse event that led to a secondary surgery are considered treatment failures (per another of the FDA’s requests), the data continue to show statistical significance for the primary endpoint in both the 397 randomized, treated and eligible population and the 414 randomized and treated population.
- Augment is non-inferior to autograft in achieving the primary endpoint in the following three populations: (1) all 397 subjects (the randomized, treated, and eligible population) who were properly randomized and treated and met all of the screening and operative inclusion/exclusion criteria and were thus eligible to participate in the study (61.2% for Augment and 62.0% for autograft, p = 0.038); (2) all 414 randomized and treated subjects evaluated based on their actual results (61.0% for Augment and 62.7% for autograft, p = 0.048); and (3) all 414 randomized and treated subjects, including those who did not meet all of the screening and operative inclusion/exclusion criteria and therefore were not eligible to participate in the study despite being treated, considered failures, per the FDA’s request (58.5% for Augment and 59.9% for autograft, p = 0.045). Consequently, Augment met its primary endpoint in all of the randomized and treated subjects, regardless of whether ineligible subjects were excluded from the analysis, evaluated based on their actual results or treated as failures.
- Success or failure on CT scans is highly correlated to the clinical outcome of the subject. When the Company analyzed the data to determine whether CT success is correlated with beneficial changes in clinical and functional outcome scores, these data showed that subjects with CT success averaged significantly better clinical and functional outcome scores than subjects with CT failures.
- No differences exist between treatment groups across the detailed subgroup analyses specifically requested by the FDA or additional subgroups identified by the Company. The Company examined literally thousands of empirical cumulative distribution functions and found no evidence of differences in score distributions between the two treatment groups. For example, Augment and autograft yielded equivalent results in over 2,000 empirical cumulative distribution function plots requested by the Agency.
- In the subgroup analyses specifically requested and defined by the FDA, including stratification by volume of graft used, even in patients with the most severe defects requiring the highest volume of graft (7-9 cc), Augment and autograft performed equivalently, with both groups exhibiting a 48% CT fusion rate for the primary endpoint. Therefore, in our view Augment and autograft behave similarly in radiologic, clinical and functional outcomes across a broad array of subgroups of the subjects in this trial.
- In accordance with the Company’s belief, based on discussions with the FDA’s Center for Devices and Radiological Health (CDRH) senior management, no black box warning should be required for Augment. This view is in agreement with both oncologists on the Orthopaedic and Rehabilitation Devices Panel of the FDA’s Medical Devices Advisory Committee (Advisory Panel) that Augment poses no demonstrable safety risk, and is further supported by new data presented in the amendment. For example, a human PK study has now been completed which demonstrates that there is no detectable systemic exposure of rhPDGF-BB from local implantation of a large volume of Augment in foot and ankle fusions, mitigating any theoretical systemic safety concern. Nonetheless, as requested by the FDA, the Company has proposed a post-approval program. This program encompasses a continuing follow-up on the patients enrolled in the pivotal trial as well as a patient registry to continue to monitor the safety of Augment in commercial use.
- The new cell-based neutralizing antibody assay requested by the FDA resulted in seven subjects (2.6% of all Augment-treated subjects) presenting with transient neutralizing antibodies at one time point. All seven of the subjects who exhibited a neutralizing response returned to baseline levels at the following time point. Assessment of the clinical efficacy and safety data from the seven patients indicate that there is no apparent clinical consequence of this transient immune response.
- The morbidity from autograft harvest during foot and ankle surgery is substantial, with nearly one in 10 subjects experiencing clinically significant donor site pain for a year post-surgery (and one in eight at six months), regardless of donor site location. Augment patients had equivalent effectiveness outcomes without any increased pain or risk of related complications due to bone graft harvest procedure.
BioMimetic Therapeutics Submits Augment® Bone Graft PMA Amendment To FDA
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts